The new Cervical Cancer treatment, pembrolizumab, will be made available immediately to patients in the UK under a fast-track drug deal. Clinical trials have shown that adding pembrolizumab to standard treatment (chemotherapy) may help to extend patients’ lives by up to eight months on average.

The post New Cervical Cancer Drug could extend patients’ lives by eight months appeared first on Balanced News Summary.